Novo Nordisk’s new diabetes pill Rybelsus will be covered by Express Scripts Holding Co., one of the largest U.S. pharmacy benefit managers, the Danish drugmaker said on Friday.
Cigna Corp. agreed to sell the health insurer’s disability and accidental death insurance unit for company employees to New York Life Insurance Co. in a $6.3 billion deal.
Cigna introduced a plan to fully cover costs for expensive gene therapies, eliminating any out-of-pocket payments for customers.
Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.
Expectations were high during 2018 for three new migraine drugs hitting the market from Amgen Inc., Eli Lilly and Co. and Teva Pharmaceutical Industries Ltd. Priced around $7,000 each, the drugmakers called them “breakthrough” treatments designed to prevent migraines when taken year-round, and estimated that millions of patients could benefit. But a small group of medical experts who quietly advise U.S. health insurers on new drugs was not impressed, according to a private meeting held at UnitedHealth Group’s OptumRx offices in Chicago that was attended by Reuters.
Teva Pharmaceutical Industries said a European Medicines Agency panel recommended approving the migraine treatment Ajovy, a drug being counted on to revive the company’s fortune.
CVS Health Corp. – a top U.S. manager of pharmacy benefits – added new migraine drugs from Teva Pharmaceutical Industries Ltd. and Eli Lilly and Co. to the PBM’s list of covered drugs, excluding a rival treatment from Amgen Inc.
Pharmacy chain CVS Health Corp. won U.S. antitrust approval for the $69 billion acquisition of health insurer Aetna Inc., the Justice Department said.
Merck & Co. CEO Kenneth Frazier, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.
Gilead Sciences Inc. plans to launch generic versions of the company’s hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.